Test For Named Compound Or Class Of Compounds Patents (Class 436/815)
-
Patent number: 6558961Abstract: Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the individual are provided.Type: GrantFiled: September 3, 1999Date of Patent: May 6, 2003Assignee: PowderJect Research LimitedInventors: David F. Sarphie, Lee K. Roberts, Deborah L. Fuller
-
Patent number: 6558956Abstract: Techniques and devices for detecting and analyzing controlled substances and the like are discussed including highly reactive sensor molecules which are coated on a spectroscopic sample surface (4) and which may chemically react with a given analyte to form a covalently bonded adduct with spectral characteristics unique to the new adduct. The techniques provide the basis of a detection system with high sensitivity and high specificity in which the surface can even be washed to remove interfering or nonreactive compounds. The sensor molecules which comprise the coating (8) may have three major components: a central molecular scaffold (“CMS”), a “tether” terminated by a surface attachment group “SAG,” and a reactive functional group “RFG” which may be highly reactive towards certain classes of molecules.Type: GrantFiled: December 17, 1999Date of Patent: May 6, 2003Assignee: The University of WyomingInventors: Keith T. Carron, Robert C. Corcoran
-
Patent number: 6534282Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETs) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by subtracting the amounts of NADPH-independent epoxyeicosatriencic acids (EETs) from total (NADPH-dependent+independent) EETs.Type: GrantFiled: September 4, 2001Date of Patent: March 18, 2003Inventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz
-
Patent number: 6521615Abstract: This invention provides a method of treating an animal with pyrophosphate gout or osteoarthritis comprising administering an effective amount of a calcium antagonist, thereby reducing calcium pyrophosphate crystal deposition in the animal.Type: GrantFiled: January 4, 2001Date of Patent: February 18, 2003Assignee: The Regents of the University of CaliforniaInventor: J. Edwin Seegmiller
-
Patent number: 6509462Abstract: The present invention provides a highly sensitive immunoassay system for estrogens, which utilizes as a labeled compound a biotinylated estradiol derivative of the formula (1) wherein one of R1 and R2 is hydrogen and the other is a group represented by wherein R3s are the same or different and represent an arginine residue or a lysine residue, x is 0 or 1, y is an integer from 1 to 5, and z is an integer from 1 to 3.Type: GrantFiled: July 17, 2001Date of Patent: January 21, 2003Assignees: Otsuka Pharmaceutical Co., Ltd., Yanaihara Institute, Inc.Inventors: Noboru Yanaihara, Ikuo Kato, Kazuyuki Kitamura, Tsukasa Kodaira
-
Patent number: 6495352Abstract: A method for encapsulating organic molecules, and in particular, biomolecules using sol-gel chemistry. A silica sol is prepared from an aqueous alkali metal silicate solution, such as a mixture of silicon dioxide and sodium or potassium oxide in water. The pH is adjusted to a suitably low value to stabilize the sol by minimizing the rate of siloxane condensation, thereby allowing storage stability of the sol prior to gelation. The organic molecules, generally in solution, is then added with the organic molecules being encapsulated in the sol matrix. After aging, either a thin film can be prepared or a gel can be formed with the encapsulated molecules. Depending upon the acid used, pH, and other processing conditions, the gelation time can be from one minute up to several days. In the method of the present invention, no alcohols are generated as by-products during the sol-gel and encapsulation steps.Type: GrantFiled: April 13, 2000Date of Patent: December 17, 2002Assignee: Sandia CorporationInventors: C. Jeffrey Brinker, Carol S. Ashley, Rimple Bhatia, Anup K. Singh
-
Patent number: 6489119Abstract: Disclosed is a method of selecting analgesic agents based on their selective ability to block tetrodotoxin-insensitive sodium channels, particularly in comparison to blocking tetrodotoxin-sensitive sodium channels. Also disclosed is a novel class of compounds that is selective for blocking tetrodotoxin-insensitive sodium channels.Type: GrantFiled: December 6, 1999Date of Patent: December 3, 2002Assignee: Elan Pharmaceuticals, Inc.Inventors: James L. Miller, George P. Miljanich, Stephen S. Bowersox, Laszlo Nadasdi
-
Patent number: 6489113Abstract: A system of diagnostic test methods are provided for diagnosing whether a primary breast tumor from an individual human subject is a clinically metastatic tumor. These in-vitro diagnostic methods detect and utilize the presence or absence of a 55 kilodalton protein for the DNA or the RNA coding for an expressing this protein as a marker and indicator of tumor metastasis. The test methods thus can detect either the presence of the protein itself, or its unique DNA, or its singular RNA individually or collectively. Each method of detection provides a reliable indicator and marker by which to clinically diagnose and determine if a primary tumor within the breast of a living human subject is now or will soon likely be a metastatic tumor.Type: GrantFiled: October 7, 2000Date of Patent: December 3, 2002Assignee: Boston UniversityInventor: Abdulmaged M. Traish
-
Patent number: 6485987Abstract: The present invention relates to methods and compositions for the direct detection of analytes using color changes that occur in immobilized biopolymeric material in response to selective binding of analytes to their surface. In particular, the present invention provides methods and compositions related to the encapsulation of biopolymeric material into metal oxide glass using the sol-gel method.Type: GrantFiled: February 8, 2000Date of Patent: November 26, 2002Assignees: Regents of the University of California, Sandia CorporationInventors: Deborah H. Charych, Darryl Sasaki, Stacey Yamanaka
-
Patent number: 6482648Abstract: The present invention relates to methods for the production of a stable troponin preparation and its use as a calibrator and/or control in immunoassays. The formulation is prepared from mammalian, preferably bovine, heart tissue which provides a calibrator/control composition which remains stable over a long period of time.Type: GrantFiled: October 14, 1997Date of Patent: November 19, 2002Assignee: Bayer CorporationInventors: Margit Doth, Christoph Petry
-
Patent number: 6472222Abstract: A simple screening method is provided for determining biological variations among individuals in a smoking cessation program so that a therapy regimen can be adjusted appropriately for each individual. The method includes the steps of having an individual intake a predetermined dose of nicotine, taking a saliva sample at a predetermined time subsequent to intake of the dose of nicotine, and measuring the nicotine and cotinine levels in the sample. Thereafter, a ratio is calculated which includes both the nicotine and cotinine levels as an indicator of the rate of nicotine metabolism of the individual being screened.Type: GrantFiled: February 16, 1999Date of Patent: October 29, 2002Assignee: Via Christi Research, Inc.Inventor: W. Dale Horst
-
Patent number: 6465194Abstract: Hybridoma cell lines have been generated which produce and secrete monoclonal antibodies which selectively bind to 4,4′-dinitrocarbanilide (DNC), the active agent of nicarbazin. These hybridomas may be obtained by using as an immunization agent or immunogen, p-nitroaniline which has been conjugated to an immunogenic carrier. DNC in biological samples may be detected and quantified by contacting the sample with the antibodies to form a DNC/antibody immunocomplex when DNC is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of DNC and/or nicarbazin.Type: GrantFiled: November 29, 2000Date of Patent: October 15, 2002Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Ross C. Beier, Larry H. Stanker, Colin R. Young
-
Patent number: 6455322Abstract: The invention provides a competition binding assay for detecting P2YADP receptor ligands.Type: GrantFiled: January 6, 2000Date of Patent: September 24, 2002Assignee: AstraZeneca ABInventor: Ian P. Kirk
-
Patent number: 6451618Abstract: The present invention is a method and kit for analyzing a sample, preferably a liquid environmental sample, which may comprise a toxic xenobiotic element or compound, i.e., an environmental pollutant. The method and kit preferably utilize a portion of a molecule comprising a peptide zinc binding domain, known as a zinc finger.Type: GrantFiled: February 2, 2001Date of Patent: September 17, 2002Assignee: The Board of Regents of the University of OklahomaInventor: Jay S. Hanas
-
Patent number: 6440749Abstract: The present invention relates to compositions and methods for inhibiting and reversing nonenzymatic cross-linking (protein aging). Accordingly, compositions are disclosed which comprise an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins, and which additionally reverse pre-formed crosslinks in the advanced glycosylation endproducts by cleaving alpha-dicarbonyl-based protein crosslinks present in the advanced glycosylation endproducts. Certain agents useful are thiazolium salts. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated. A immunoassay for detection of the reversal of the nonenzymatic crosslinking is also disclosed.Type: GrantFiled: December 22, 1999Date of Patent: August 27, 2002Assignees: Alteon. Inc., The Picower Institute for Medical ResearchInventors: Anthony Cerami, Peter C. Ulrich, Dilip R. Wagle, San-Bao Hwang, Sara Vasan, John J. Egan
-
Patent number: 6440682Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETS) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by measuring the amounts of NADPH-independent epoxyeicosatrienoic acids (EETs) and total (NADPH-dependent+independent) EETs.Type: GrantFiled: May 24, 2000Date of Patent: August 27, 2002Assignee: Detroit R&D Inc.Inventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz
-
Patent number: 6432656Abstract: The present invention features calcilytic compounds. “calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.Type: GrantFiled: August 6, 1999Date of Patent: August 13, 2002Assignee: NPS Pharmaceuticals, Inc.Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
-
Patent number: 6410696Abstract: A method of measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is disclosed. A method of inactivating interfering cross-reactive material in an assay for measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is also disclosed. Compositions wherein cyclosporin is conjugated to an immunogenic carrier or a label, optionally through a linking group, at an alanine nitrogen atom of the cyclic backbone of cyclosporin are also disclosed. Compositions wherein atiocyclosporin is conjugated, optionally through a linking group, to an immunogenic carrier or a label are also disclosed. Where cyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing cyclosporin.Type: GrantFiled: November 13, 2000Date of Patent: June 25, 2002Assignee: Dade Behring Marburg GmbHInventors: Dariush Davalian, Maureen H. Beresini, Svetlana Alexander, Mae Wan-Leng Hu, Edwin F. Ullman
-
Patent number: 6410341Abstract: An analytical test device is described for the immunochromatographic determination of the presence of one or more analytes in fluid samples. The device is configured such that the sample is allowed to enter the detection zone simultaneously from many different directions, eliminating stagnation of the flow of the sample. By selection of the porous substrate, the device also allows for the separation of red blood cells from plasma, providing a rapid test for one or more analytes in a sample of whole blood. The device of the present invention may measure more than one analyte simultaneously from a single sample, either by having multiple immunochromatographic pathways fed by a single sample, or multiple analytes detected in the same pathway by way of multiple capture antibodies.Type: GrantFiled: July 14, 1999Date of Patent: June 25, 2002Assignee: Spectral Diagnostics, Inc.Inventors: Helmut E. Freitag, Qinwei Shi, Charles A. Harrington
-
Patent number: 6410340Abstract: We have identified and purified to homogeneity from lymphatic tissues a 8.4 kDa immunophilin that specifically and avidly binds the immunosuppressant drugs FK-506 (Kd=0.8 nM) and rapamycin (Kd=0.08 nM) and their pharmacologically active metabolites and derivatives, but does not bind cyclosporin A. The isolated 8.4 kDa protein appears to be identical to authentic human and bovine ubiquitins in all measured respects (partial amino acid sequence, molecular weight, binding constants, binding specificity, biochemical aspects, and utility as the protein binding reagent in binding assays for immunosuppressant drugs in fluid samples, including patient blood). The availability of commercial quantities of human recombinant ubiguitin removes a supply barrier to the use of immunophilin protein binding assays for the estimation of FK-506, rapamycin and pharmacologically active metabolites and derivatives in the clinical setting.Type: GrantFiled: August 23, 2000Date of Patent: June 25, 2002Assignee: Children's Research InstituteInventor: Steven J. Soldin
-
Patent number: 6399318Abstract: The present invention provides an immunoassay for phthalic acid esters, which comprises measuring the phthalic acid esters contained in a sample using an antibody produced with a conjugate of a carrier protein and a phthalic acid ester derivative represented by the formula wherein R1 and R2 may be the same or different and are hydrogen, alkyl, cycloalkyl or phenylalkyl, with the proviso that both of R1 and R2 are not hydrogen; m is an integer from 1 to 5; and Y is amino or carboxyl.Type: GrantFiled: October 30, 2001Date of Patent: June 4, 2002Assignees: Otsuka Pharmaceutical Co., Ltd., Yanaihara Institute Inc.Inventors: Noboru Yanaihara, Ikuo Kato, Shingo Nagasawa, Tsukasa Kodaira
-
Patent number: 6387639Abstract: Ma family polypeptides Ma1, Ma2, Ma3, Ma4 and Ma5 are disclosed, as are nucleic acids encoding the Ma family polypeptides, antibodies that bind to Ma family polypeptides, and methods of diagnosis of paraneoplastic syndromes, by assessing a test sample from an individual for the presence or absence, or amount, of antibodies to Ma family polypeptides.Type: GrantFiled: November 10, 1998Date of Patent: May 14, 2002Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Jerome B. Posner, Josep O. Dalmau, Myrna R. Rosenfeld
-
Patent number: 6383819Abstract: The present disclosure relates to a method for determining cholesterol in low density lipoprotein comprising the steps of (a) measuring total cholesterol level in a sample containing at least high density lipoprotein, low density lipoprotein, very low density lipoprotein and chylomicron, and (b) measuring cholesterol levels in the high density lipoprotein, very low density lipoprotein and chylomicron in the sample, wherein the cholesterol level in the low density lipoprotein is determined by subtracting a value obtained in step (b) from a value obtained in step (a). The present invention enables concurrent determination of cholesterol level in low density lipoprotein and total cholesterol level, facilitating acquisition of two types of biological information at a time.Type: GrantFiled: January 27, 2000Date of Patent: May 7, 2002Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Motokazu Watanabe, Toshihiko Yoshioka, Shiro Nankai
-
Patent number: 6368814Abstract: The present invention is directed to novel tricyclic antidepressant drug derivatives synthesized for covalent attachment to proteins or polypeptide antigens for use in the preparation of antibodies or receptors to tricyclic antidepressant drugs and tricyclic antidepressant metabolites. The new derivatives are characterized by a saturated double bond on the amitriptyline portion of the molecule and are represented by the structure where R1 is a saturated or unsaturated, substituted or unsubstituted, straight or branched chain of 0-10 carbon or heteroatoms, X is a linker group consisting of 0-2 substituted or unsubstituted aromatic rings, and Y is an activated ester or NH—Z, where Z is a poly(amino acid).Type: GrantFiled: December 22, 2000Date of Patent: April 9, 2002Assignee: Roche Diagnostics CorporationInventors: Mitali Ghoshal, Jane S. C. Tsai, Stephen Vitone
-
Patent number: 6365129Abstract: A high throughput toxicology screening method is provided. In the subject method, at least 10 different compound compositions are tested simultaneously. Each compound composition is tested by contacting it with a plurality, e.g. from about 10 to 1000, of non-mammalian multi-cellular organisms and determining the effect of the compound composition on the organisms. The multi-cellular organisms employed in the subject methods are small, have differentiated tissues and organs and have a rapid generation time. The subject high throughput screening methods find use in a variety of applications, and are particularly suited for use in the toxicology screening of libraries of compounds, such as libraries of combinatorially produced compounds.Type: GrantFiled: December 27, 1999Date of Patent: April 2, 2002Assignee: Tosk, Inc.Inventor: Patrick Fogarty
-
Patent number: 6352863Abstract: An assay device and method are provided which allow the determination of the presence or absence of at least one analyte in a test sample, while providing specific identification of the test subject. The assay device includes a reaction medium having at least one reaction zone and at least one control zone, which is capable of providing a pattern suitable for identifying the test subject. The pattern suitable for identifying the test subject is preferably a fingerprint. In a preferred embodiment of the invention, the reaction zone and the control zone include at least one member of a ligand/receptor pair.Type: GrantFiled: January 27, 1997Date of Patent: March 5, 2002Assignee: La Mina, Inc.Inventor: Raouf A. Guirguis
-
Patent number: 6350579Abstract: A method and compositions for the detection and/or quantification of an analyte through the use of a plurality of labeled probes, with two or more said probes targeted to different regions of said analyte. In specific embodiments, the labels are separately distinguishable, and/or are present at different specific activities on the labels.Type: GrantFiled: August 28, 2000Date of Patent: February 26, 2002Assignee: Gen-Probe IncorporatedInventor: Norman C. Nelson
-
Patent number: 6329155Abstract: Amyloid precursor protein (APP) processing which is activated by cell-surface neurotransmitter receptors, is described. An assay for testing an agent for the capacity to regulate, and particularly to stimulate, secretion of amyloid precursor protein (APP), a description of the characteristics of agents identified by the assay, and a method of altering APP processing in an individual are also disclosed. The assay, agents, and method of altering APP processing are particularly useful for the treatment and prevention of diseases involving APP processing, such as Alzheimer's disease.Type: GrantFiled: April 15, 1994Date of Patent: December 11, 2001Assignee: Massachusetts Institute of TechnologyInventors: Roger M. Nitsch, Barbara E. Slack, Richard J. Wurtman, John H. Growdon
-
Patent number: 6326159Abstract: Receptors are disclosed that are antibodies that exhibit a binding affinity for an immune complex of a monoepitopic antigen and an antibody for such antigen that is substantially greater than the binding affinity for the monoepitopic antigen or the antibody for the monoepitopic antigen apart from the immune complex. Normally, the monoepitopic antigen has a molecular weight less than 1500 and is an organic compound. The antibodies of the present invention find use in a method for determining a monoepitopic antigen in a sample suspected of containing such antigen. The method comprises forming an immune sandwich complex comprising the monoepitopic antigen or an analog thereof, a first monoclonal antibody that binds to the monoepitopic antigen, and a second monoclonal antibody that is an antibody of the present invention and detecting the immune sandwich complex.Type: GrantFiled: September 2, 1994Date of Patent: December 4, 2001Assignee: Dade Behring Marburg GmbHInventors: Edwin F. Ullman, John Jelesko, Marcel R. Pirio, Thomas D. Kempe
-
Patent number: 6319721Abstract: A method capable of showing a color change sufficient for indicating the presence and/or concentration of a protein in a protein-containing liquid sample by contacting with the sample, comprising: indium or an induim compound, and a dye or pigment capable of forming a complex with indium.Type: GrantFiled: December 23, 1999Date of Patent: November 20, 2001Assignee: Kyoto Daiichi Kagaku Co., Ltd.Inventor: Hideko Kosaka
-
Patent number: 6313274Abstract: A protein containing one or more disulfide bonds, e.g., an antibody, is subjected to ultraviolet radiation to reduce one or more such bonds to reactive sulfhydryl groups; the resulting photoactivated protein is reacted with other chemical entity which is reactive with sulfhydryl, such as certain radiometals, chelating agents, drugs and toxins, so as to obtain a conjugate useful in, e.g., in vitro diagnosis, in vivo imaging, and therapy.Type: GrantFiled: May 25, 1995Date of Patent: November 6, 2001Inventors: Thomas R. Sykes, Thomas K. Woo, Antoine A. Noujaim, Pei Qi
-
Patent number: 6306616Abstract: The invention relates to an assay system for the improved detection of analytes, and the ability to distinguish them from cross-reacting substances. Samples giving a positive reaction in a direct assay test are treated with a neutralizing antibody that inhibits reactivity of the true analyte, but not the interfering substance. In adsorption type confirmatory assays, the neutralizing antibody is provided in an amount sufficient to adsorb the analyte but not all of the interfering substance. When retested in an immunoassay, the neutralized sample gives a negative result if it originally contained the true analyte. Samples giving a positive reaction in both the direct and confirmatory tests are marked as containing an interfering substance. The confirmatory assay easily distinguishes the true analyte and reduces the rate of false positives, even when the interfering substance is unknown and present at high concentration.Type: GrantFiled: March 27, 1998Date of Patent: October 23, 2001Assignee: Microgenics CorporationInventor: Jeffrey E. Shindelman
-
Patent number: 6300082Abstract: A method and apparatus for measuring binding between a plurality of molecules of a biological receptor protein and a plurality of molecules of a type which binds to said biological receptor is presented. Apparatus utilizes a sensor possessing a waveguide to which have been attached in close proximity to its surface, features resembling molecules having binding affinity for said biological receptor. Light is injected into said waveguide so as to produce an evanescent field at its surface. Molecules of receptor protein are tagged with a tag belonging to that class of chemicals which alters a characteristic of light, when said light passes through said chemical tag. Apparatus utilizes a rapid means of monitoring the change in optical signal coming from the waveguide as binding proceeds between tagged receptor protein and the binding molecular feature of the waveguide. This allows direct measurement of binding and dissociation rates between the receptor and the binding feature of the waveguide.Type: GrantFiled: March 20, 1998Date of Patent: October 9, 2001Assignee: IA, Inc.Inventors: Judith L. Erb, James G. Downward, IV, John R. Erb-Downward, James L. Wittliff
-
Patent number: 6297020Abstract: Disclosed is an improvement to a dry assay device for determining the concentration of a first analyte in a sample of body fluid and a second analyte in the same sample of body fluid. The device involves the use of a strip of an absorbent material through which the sample of body fluid flows and wherein the first analyte is determined calorimetrically in a first region of the strip and the second analyte is determined by an immunoassay which takes place in a second region of the strip located downstream from the first region. The improvement involves placing the strip in a hollow casing having a top and a bottom and which is so constructed that when the top and bottom of the casing are mated there is formed a U shaped, body fluid impervious barrier around the first region of the strip to prevent the sample of body fluid from flowing in any direction other than in the direction of the second region of the strip.Type: GrantFiled: March 1, 1999Date of Patent: October 2, 2001Assignee: Bayer CorporationInventor: David A. Brock
-
Patent number: 6284550Abstract: An improved multi-layered diagnostic sanitary test strip for receiving a heterogenous fluid, such as whole blood, to test for presence and/or amount of a suspected analyte in the fluid by facilitating a color change in the strip corresponding to the amount of the analyte in the fluid, wherein the test strip includes fluid volume control dams to prevent spillage of the fluid from the strip and a chemical reagent solution that facilitates end-point testing. The improved test strip comprises (a) an upper support strip having a fluid receiving port and (b) a lower support strip having a color change viewing port and securely sandwiched therebetween (c) a spreading mesh screen for uniformly distributing the fluid, (d) a chemically treated separating layer for removing an undesirable element, e.g.Type: GrantFiled: June 25, 1999Date of Patent: September 4, 2001Assignee: Home Diagnostics, Inc.Inventors: Patrick Carroll, Jon Schneider, Douglas E. Bell
-
Patent number: 6277584Abstract: Calibration of an assay by converting an analyzer's normal signal response through an arithmetic function prior to performing the curve fit, thereby improving the accuracy of the curve fit in a region of greatest diagnostic interest.Type: GrantFiled: December 16, 1998Date of Patent: August 21, 2001Assignee: Dade Behring Inc.Inventors: Victor Pichai Chu, Connie Mary Sanders, James Floyd Pierson-Perry, Tie Quan Wei
-
Patent number: 6274334Abstract: A hybridoma cell line has been produced for secreting a monoclonal antibody that binds ractopamine and is effective to detect ractopamine levels of about 1 ng/mL or lower. This monoclonal antibody may be used for the detection and quantitative determination of trace amounts of ractopamine in samples, especially in animal tissue, body fluids and feed material.Type: GrantFiled: July 13, 2000Date of Patent: August 14, 2001Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Weilin L. Shelver, David J. Smith
-
Patent number: 6274328Abstract: The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject.Type: GrantFiled: September 3, 1998Date of Patent: August 14, 2001Assignee: Xoma CorporationInventors: Mark Leslie White, Stephen Fitzhugh Carroll, Jeremy Kam-kuen Ma
-
Patent number: 6255117Abstract: A test method and device are described for quantitatively determining the presence and concentration of monopersulfate ion in aqueous solution. Contacting the aqueous solution containing monopersulfate ion with a test strip in accordance with the invention produces a color change in proportion to the concentration of the ion. The invention has particular utility in maintaining the proper level of sanitizers in swimming pool water.Type: GrantFiled: June 4, 1999Date of Patent: July 3, 2001Assignee: Lamotte CompanyInventor: Lydia Johnson
-
Patent number: 6235538Abstract: The present invention is a method and kit for analyzing a sample, preferably a liquid environmental sample, which may comprise a toxic xenobiotic element or compound, i.e., an environmental pollutant. The method and kit preferably utilize a portion of a molecule comprising a peptide zinc binding domain, known as a zinc finger.Type: GrantFiled: March 4, 1998Date of Patent: May 22, 2001Assignee: The Board of Regents of the University of OklahomaInventor: Jay S. Hanas
-
Patent number: 6232130Abstract: A method of evaluating a carbohydrate in a sample. The method includes providing a low valency carbohydrate binding ligand, providing a glycoconjugate which includes a label, and a carbohydrate moiety, contacting the low valency carbohydrate binding ligand and the glycoconjugate with the sample, determining the extent of binding of the low valency carbohydrate binding ligand with the glycoconjugate, the binding of the low valency carbohydrate binding ligand with the glycoconjugate being correlated with the amount of carbohydrate in the sample.Type: GrantFiled: June 4, 1998Date of Patent: May 15, 2001Assignee: Sensor Technologies, Inc.Inventor: David E. Wolf
-
Patent number: 6225073Abstract: The present invention provides antibodies useful in assays for mycophenolic acid (MPA). These antibodies bind MPA and are able to distinguish MPA from its esters, such as morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate, and/or its metabolites, such as mycophenolic acid glucuronide. The present invention also provides conjugates of labels and MPA or MPA analogs. The antibodies of the invention are capable of binding these conjugates and are also capable of inhibiting the activity of the label when bound to the conjugates. The present invention also provides methods for the determination of MPA in a sample suspected of containing MPA that use the antibodies and/or conjugates of the invention. The present invention also provides assay reagents as well as packaged kits useful for performing the methods of the invention.Type: GrantFiled: July 7, 1994Date of Patent: May 1, 2001Assignee: Dade Behring Marburg GmbHInventors: Svetlana Alexander, Dariush Davalian
-
Patent number: 6214629Abstract: An analytical test device is described for the immunochromatographic determination of the presence of one or more analytes in fluid samples. The device is configured such that the sample is allowed to enter the detection zone simultaneously from many different directions, eliminating stagnation of the flow of the sample. By selection of the porous substrate, the device also allows for the separation of red blood cells from plasma, providing a rapid test for one or more analytes in a sample of whole blood. The device of the present invention may measure more than one analyte simultaneously from a single sample, either by having multiple immunochromatographic pathways fed by a single sample, or multiple analytes detected in the same pathway by way of multiple capture antibodies.Type: GrantFiled: July 14, 1999Date of Patent: April 10, 2001Assignee: Spectral Diagnostics, Inc.Inventors: Helmut E. Freitag, Oinwei Shi, Charles A. Harrington
-
Patent number: 6214541Abstract: The present invention relates to a method of detecting specific antibodies directed against HPV proteins in body fluids, comprising the following steps: (I) incubating a native carrier material-bound HPV protein with body fluids, and (II) reacting specific antibodies (a) bound to the HPV protein with labeled antibodies (b) directed against antibodies (a) or with unlabeled antibodies (b) and the latter with labeled antibodies (c) directed against antibodies (b). Furthermore, this invention concerns a kit usable for this purpose.Type: GrantFiled: March 9, 1998Date of Patent: April 10, 2001Assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen RechtsInventors: Hanswalter Zentgraf, Manfred Frey, Iris Velhagen, Regina Martens, Wolfgang Meschede, Michael Pawlita, Joris Braspenning, Masimo Tommasino
-
Patent number: 6210978Abstract: Disclosed is a method for the immobilization of an analyte such as deoxypyridinium (DPD) onto a solid support. The method involves binding an antigen-amino acid-deoxypyridinium complex to the support via an anti-antigen binding partner located in a capture zone of the solid support. Preferably, the support is nitrocellulose and the antigen has the fluorescein structure.Type: GrantFiled: March 2, 1998Date of Patent: April 3, 2001Assignee: Bayer CorporationInventors: Robert P. Hatch, Meitak Teresa Yip
-
Patent number: 6210976Abstract: The invention relates to methods, compositions, kits, and devices for detecting cardiac ischemia, hypoxia, or other causes of heart failure in a mammal by obtaining a test sample from a mammal, measuring a level of a non-polypeptidic cardiac marker in the test sample, and determining if the level of the cardiac marker measured in said test sample correlates with cardiac ischemia or hypoxia or another form of heart failure.Type: GrantFiled: May 22, 1998Date of Patent: April 3, 2001Assignee: Medlyte Diagnostics, Inc.Inventor: Roger A. Sabbadini
-
Patent number: 6204005Abstract: The present invention provides a method for determining qualitatively or quantitatively the presence of toxic congeners of polychlorinated biphenyl in a test sample. The method includes the steps of: providing a known quantity of antibodies to the toxic polychlorinated biphenyl congener; providing a competitor that will bind to said antibodies in competition with the toxic polychlorinated biphenyl congener and having a lower affinity to said antibodies than said antibodies have to the toxic polychlorinated biphenyl congener; incubating said antibodies and said competitor in the presence of a test sample; and detecting the presence of the toxic polychlorinated biphenyl toxic congener in the test sample.Type: GrantFiled: March 16, 1995Date of Patent: March 20, 2001Assignee: Ecochem Research, Inc.Inventors: Robert E. Carlson, Todd A. Swanson
-
Patent number: 6203757Abstract: Diagnostic products having multiple test strips within a unitary diagnostic test device, or test icon, are described herein. In the preferred embodiments of the diagnostic test device of this invention, a fluid sample distribution system is provided wherein a sample collection and distribution port is provided in the housing for receipt of a biologic fluid sample and the channeling of such sample onto a sample receiving web. The sample receiving web, which is located within the test device, is in fluid communication with an array of test strips, and is configured to deliver an aliquot of biologic fluid sample to the test site of each such test strip at essentially the same rate. In the preferred embodiments of this invention, the sample receiving web comprises at least one base segment and at least one branched segment. Each of the base and branched segments can be formed or cut from a common sheet of material or from separate sheet material and thereafter placed in contiguous relationship one another.Type: GrantFiled: December 2, 1998Date of Patent: March 20, 2001Assignee: Bionike, Inc.Inventors: Frank Lu, Liang Chan
-
Patent number: 6194552Abstract: The antitope of an antibody is masked with a masking agent, followed by immobilization on a support. The masking agent is then eluted to produce an improved immunosorbent, which is capable of binding more than double the amount of an antigen than existing immunosorbents having the same antibody bound at the same density. Preferably, the masking agent is an antigen or other compound having an epitope for which the antitope of the bound antibody has an avidity. In a preferred embodiment, greater than 30% of the bound antibodies maintain the same vicinity as when unbound for specific antigen or hapten molecules. Preferably, the support is formed of any conventional immunosorbent support material which allows the bound and unbound antibody to maintain an avidity for the same compounds or antigens.Type: GrantFiled: August 19, 1994Date of Patent: February 27, 2001Assignee: Center for Innovative TechnologyInventors: William H. Velander, Carolyn Orthner
-
Patent number: 6190921Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.Type: GrantFiled: January 20, 1999Date of Patent: February 20, 2001Inventors: Pekka Juhani Leppäluoto, Lauri Erkki Olli Vakkuri, Olli Jaakko Vuolteenaho